T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330

Preclinical and emerging clinical studies demonstrate that bispecific T-cell engaging (BiTE) antibody constructs can potently lyse targeted tumor cells, but the determinants for their activity remain incompletely understood. Using human acute myeloid leukemia (AML) cell lines engineered to overexpre...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Cancer J
Hlavní autoři: Laszlo, G S, Gudgeon, C J, Harrington, K H, Walter, R B
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2015
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4558592/
https://ncbi.nlm.nih.gov/pubmed/26295610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2015.68
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky